Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations

Launched by RENJI HOSPITAL · Apr 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called norepinephrine, combined with a specific approach to managing fluids (called goal-directed fluid therapy), can help reduce the chances of delayed graft function (DGF) after kidney transplantation. DGF is a condition that affects many patients after receiving a new kidney, making it necessary for them to undergo dialysis within the first week post-surgery. By exploring this combination treatment, researchers hope to find better ways to care for patients during and after their kidney transplant surgeries.

To participate in this trial, individuals must be at least 18 years old and scheduled for a kidney transplant using a kidney from a deceased donor. Participants will need to sign a consent form to join the study. This trial is currently looking for volunteers and is open to all genders. If you decide to join, you can expect to receive close monitoring and care throughout the process to help improve outcomes after your transplant. Remember, if you have certain medical conditions or are involved in other clinical trials, you may not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Recipients aged 18 years or older
• • 2. Scheduled to undergo kidney transplantations under general anesthesia
• • 3. Cadaveric kidney transplantations
• • 4. Sign the informed consent form
• Exclusion Criteria:
• • 1. Donors aged under 18 years
• • 2. Donor kidneys classified as Maastricht category I or II
• • 3. Contraindications to radial artery catheterization
• • 4. Pregnancy
• • 5. Cardiac dysfunction (exercise tolerance less than 4 METS)
• • 6. Severe liver dysfunction (Child Pugh C-grade)
• • 7. Respiratory diseases with tidal volume intolerance exceeding 8ml/kg
• • 8. Severe arrhythmias, including atrial fibrillation, frequent atrial or ventricular premature beats, moderate or severe aortic and mitral regurgitation
• • 9. Double-kidney transplantations
• • 10. Simultaneous organ or additional surgeries during kidney transplantations
• • 11. Repeat kidney transplantations
• • 12. Concurrent participation in other clinical trials
• • 13. Patients deemed ineligible by researchers